Fasting blood sugar predicts progression of non-culprit lesions in STEMI patients after primary PCI
China: Fasting blood sugar is a valuable predictor for the progression of non-culprit lesions (NCL) in ST-elevation myocardial infarction (STEMI) patients after primary percutaneous coronary intervention (PPCI), a recent study has shown. The study was featured in BMC Cardiovascular Disorders on 06 December 2022.
Primary PCI can rescue dying myocardium, improve prognosis, and reduce cardiovascular (CV) events in STEMI patients. However, recent studies have shown that non-culprit lesions may advance after PPCI, and NCL progression could significantly impact prognosis after PPCI. However, there is no clarity on the clinical correlation factors for the progression of NCL. Jian Wang from the Department of Cardiology in Xining First People's Hospital, Xining, Qinghai, China, and colleagues aimed to investigate the relationship between clinical features and the progression of non-culprit lesions in STEMI patients after primary PCI.
The authors enrolled 480 STEMI patients (57.1 ± 9.2 y) who underwent primary PCI between January 2016 and December 2017. As a treatment for culprit lesions, all patients underwent primary PCI. Angiographic and clinical follow-up was done for 12 months. Patients were divided into an NCL progression group (n=205) and a control group (n=275) based on follow-up outcomes at 12 months from angiography.
The study led to the following findings:
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.